{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:54:41Z","timestamp":1788292481040,"version":"build-2803163510"},"reference-count":96,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>A single vaccine cannot prevent or treat all cancers; however, recurrent tumor-specific epitopes may facilitate the development of pre-manufactured, HLA-matched mRNA vaccines tailored for specific molecular subgroups. We define the shared tumor-specific epitope as a recurring peptide derived from a viral oncoprotein, a driver mutation, a frameshift, an altered protein C-terminus, or a fusion junction, and we employ a rigorous cancer-cell-only criterion: a target must be recurrent within a defined subgroup, absent from essential normal tissues at the peptide\u2013HLA level, naturally presented on tumor cells, and sufficiently clonal to minimize immune escape. Under this criterion, we present fifteen sequence-anchored reference designs alongside one conceptual placeholder across thirteen candidates divided into four superclasses: viral oncoproteins (such as HPV16\/18 E6 and E7 as attenuated antigenic reference designs; Merkel cell polyomavirus serving as a design-specific placeholder), recurrent driver neoepitopes (including KRAS G12\/G13, IDH1 R132H, and H3 K27M), hematologic neoantigens (such as NPM1 Type A C-terminus; and a single CALR exon 9 construct encoding the shared novel C-terminus of types 1 and 2 mutations), and fusion junctions (notably EWS-FLI1 and BCR-ABL). Each open reading frame is anchored to a canonical accession with its documented event; representative ORFs are provided as reference designs, with the intended residue-level verification records. These sequence designs are intended as reference constructs and are not suitable as clinical-grade or manufacturing-ready products; they require independent residue-level validation and comprehensive safety assessments prior to laboratory or clinical application. The historical record of non-personalized vaccination\u2014including HPV and hepatitis B prophylaxis, intravesical BCG, and unsuccessful tumor-associated antigen trials\u2014frames both the potential and limitations of such approaches. The practical product is not a universal vaccine but rather a governed library aligned with specific genotype, viral etiology, HLA context, and clinical setting. Currently, none of these designs have established proof-of-benefit-tier evidence.<\/jats:p>","DOI":"10.3390\/biom16071015","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:28:27Z","timestamp":1783927707000},"page":"1015","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequence-Anchored Shared Tumor-Specific Epitopes for Pre-Manufactured HLA-Matched mRNA Cancer Vaccine Libraries: A Pan-Cancer Framework"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-0336","authenticated-orcid":false,"given":"Sarfaraz K.","family":"Niazi","sequence":"first","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study","volume":"101","author":"Chang","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_5","unstructured":"European Association of Urology (2026). Disease Management. EAU Guidelines on Non-Muscle-Invasive Bladder Cancer, European Association of Urology. Available online: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer\/chapter\/disease-management."},{"key":"ref_6","unstructured":"U.S. Food and Drug Administration (FDA) (2026, June 01). FDA Approves Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer."},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration (2026, June 01). IMLYGIC (Talimogene Laherparepvec). FDA Cellular and Gene Therapy Products, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/imlygic."},{"key":"ref_8","unstructured":"U.S. Food and Drug Administration (2026, June 01). PROVENGE (Sipuleucel-T). FDA Cellular and Gene Therapy Products, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/provenge-sipuleucel-t."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdv104","article-title":"Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses","volume":"26","author":"Mitchell","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_14","unstructured":"Roswell Park Comprehensive Cancer Center (2026, May 01). CIMAvax Lung Cancer Vaccine. Available online: https:\/\/www.roswellpark.org\/cimavax."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/mc.23190","article-title":"Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development","volume":"59","author":"Pulliam","year":"2020","journal-title":"Mol. Carcinog."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Riley","year":"2016","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Narayan, R., Olsson, N., Wagar, L.E., Medeiros, B.C., Meyer, E., Czerwinski, D., Khodadoust, M.S., Zhang, L., Schultz, L., and Davis, M.M. (2019). Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219547"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000342164","article-title":"Tumor-associated antigens in breast cancer","volume":"7","author":"Criscitiello","year":"2012","journal-title":"Breast Care"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Tuohy, V.K., Jaini, R., Johnson, J.M., Loya, M.G., Wilk, D., Downs-Kelly, E., and Mazumder, S. (2016). Targeted vaccination against human alpha-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer. Cancers, 8.","DOI":"10.3390\/cancers8060056"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA vaccines: A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","unstructured":"National Cancer Institute (2026, June 01). BRCA Gene Mutations: Cancer Risk and Genetic Testing. National Cancer Institute Fact Sheet, Available online: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ruangapirom, L., Sutivijit, N., Teerapakpinyo, C., Mutirangura, A., and Doungkamchan, C. (2022). Identification of shared neoantigens in BRCA1-related breast cancer. Vaccines, 10.","DOI":"10.3390\/vaccines10101597"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nm.2161","article-title":"An autoimmune-mediated strategy for prophylactic breast cancer vaccination","volume":"16","author":"Jaini","year":"2010","journal-title":"Nat. Med."},{"key":"ref_31","unstructured":"ClinicalTrials.gov (2026, May 01). INO-5401 and INO-9012 with Cellectra 2000 in BRCA1\/2 Mutation Carriers. Identifier NCT04367675 [Trial-registry\/Status Source]. U.S. National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04367675."},{"key":"ref_32","unstructured":"Centers for Disease Control and Prevention (2026, June 01). HPV Vaccination, CDC, Available online: https:\/\/www.cdc.gov\/hpv\/vaccines\/index.html."},{"key":"ref_33","unstructured":"Centers for Disease Control and Prevention (CDC) (2026, June 01). Cancers Caused by HPV, Available online: https:\/\/www.cdc.gov\/hpv\/about\/cancers-caused-by-hpv.html."},{"key":"ref_34","unstructured":"National Cancer Institute (2026, June 01). Human Papillomavirus (HPV) Vaccines. National Cancer Institute Fact Sheet, Available online: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-vaccine-fact-sheet."},{"key":"ref_35","unstructured":"National Cancer Institute (2026, June 01). Infectious Agents and Cancer, Available online: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41591-025-04182-9","article-title":"Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: A phase 1b\/2 trial","volume":"32","author":"Willis","year":"2026","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: A register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","unstructured":"Public Health Scotland (2026, June 06). No Cervical Cancer Cases Detected in Vaccinated Women Following HPV Immunisation, Public Health Scotland News, Available online: https:\/\/publichealthscotland.scot\/news\/2024\/january\/no-cervical-cancer-cases-detected-in-vaccinated-women-following-hpv-immunisation\/."},{"key":"ref_40","unstructured":"National Cancer Institute Drug Dictionary (2026, May 01). HPV16 E6\/7 mRNA Vaccine BNT113 [Drug-Dictionary\/Status Source]. National Cancer Institute, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/hpv16-e6-7-mrna-vaccine-bnt113."},{"key":"ref_41","unstructured":"BioNTech (2026, May 01). BioNTech Receives FDA Fast Track Designation for mRNA Cancer Immunotherapy Candidate BNT113 in HPV16-Positive Head and Neck Cancer. Available online: https:\/\/www.biontech.com\/int\/en\/home\/mediaroom\/news\/press-releases\/2026\/01\/biontech-receives-fda-fast-track-designation-mrna-cancer.html."},{"key":"ref_42","unstructured":"BioNTech (2026, May 01). AHEAD-MERIT: A Study of BNT113 Plus Pembrolizumab in HPV16-Positive Head and Neck Squamous Cell Carcinoma. ClinicalTrials.gov Identifier NCT04534205 (sponsor trial code BNT113-01). BioNTech Clinical Trials. Available online: https:\/\/clinicaltrials.biontech.com\/trials\/BNT113-01."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_44","unstructured":"ClinicalTrials.gov (2026, May 01). A Phase 3 Study of PDS0101 and Pembrolizumab in HPV16-Positive Recurrent\/Metastatic Head and Neck Squamous-Cell Carcinoma. Identifier NCT06790966. U.S. National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06790966."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-22-1927","article-title":"A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I\/IIa Trial","volume":"28","author":"Hillemanns","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_48","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program (2026, June 01). Cancer Stat Facts: Pancreatic Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"ref_55","unstructured":"National Cancer Institute Drug Dictionary (2026, May 01). mRNA-Derived KRAS-Targeted Vaccine V941. National Cancer Institute, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/mrna-derived-kras-targeted-vaccine-v941."},{"key":"ref_56","unstructured":"ClinicalTrials.gov (2026, June 01). A Study of mRNA-5671\/V941 as Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer, or Pancreatic Adenocarcinoma. Identifier NCT03948763. U.S. National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03948763."},{"key":"ref_57","unstructured":"Fierce Biotech (2026, June 01). Merck Cuts Ties to Moderna\u2019s Early-Phase KRAS Vaccine, Leaving mRNA Specialist to Mull Next Steps. Available online: https:\/\/www.fiercebiotech.com\/biotech\/merck-cuts-ties-modernas-early-phase-kras-vaccine-leaving-mrna-specialist-mull-next-steps."},{"key":"ref_58","unstructured":"ClinicalTrials.gov (2026, June 01). A Study of mRNA-4359 Alone and in Combination with Immune Checkpoint Inhibitors in Participants with Advanced or Metastatic Solid Tumors. Identifier NCT05533697. U.S. National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05533697."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher","year":"2014","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","article-title":"A H3K27M-targeted vaccine in adults with diffuse midline glioma","volume":"29","author":"Grassl","year":"2023","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"eaba4380","DOI":"10.1126\/scitranslmed.aba4380","article-title":"Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine","volume":"14","author":"Gigoux","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: More than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_65","unstructured":"WestGene Biopharma (2026, June 01). WestGene to Advance Clinical Trials Following Dual IND Approvals for the World\u2019s First EB Virus-Related mRNA Therapeutic Cancer Vaccine WGc-043 [Company Press Release; Cited for IND-Clearance Status Only; the FDA Action Was IND Clearance Permitting Clinical Investigation, Not Product Approval, PR Newswire, Available online: https:\/\/www.prnewswire.com\/news-releases\/westgene-to-advance-clinical-trials-following-dual-ind-approvals-for-worlds-first-eb-virus-related-mrna-therapeutic-cancer-vaccine-302217424.html."},{"key":"ref_66","unstructured":"(2026, June 01). Targeted Oncology, FDA Approves IND Application for Epstein-Barr Virus mRNA Cancer vaccine WGc-043 [Trade Press; IND Clearance, Not Product Approval]. Available online: https:\/\/www.targetedonc.com\/view\/fda-approves-Epstein-barr-mrna-cancer-vaccine-wgc-043."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_68","unstructured":"BioNTech (2026, May 01). LuCa-MERIT-1: A First-in-Human Study of BNT116 in Non-Small-Cell Lung Cancer. Trial ID BNT116-01 [trial-Status Source; Results Pending]. BioNTech Clinical Trials. Available online: https:\/\/clinicaltrials.biontech.com\/trials\/BNT116-01."},{"key":"ref_69","unstructured":"BioNTech SE\/Regeneron Pharmaceuticals (2026, May 01). ClinicalTrials.gov Identifier NCT05557591; EMPOWERVAX Lung 1: A Phase 2 Study of BNT116 Plus Cemiplimab Versus Cemiplimab in Advanced PD-L1\u226550% Non-Small-Cell LUNG cancer [Trial-Status Source; No Efficacy Data Reported], Available online: https:\/\/clinicaltrials.gov\/study\/NCT05557591."},{"key":"ref_70","unstructured":"BioNTech (2026, May 01). BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma. Available online: https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-announces-positive-topline-phase-2-results-mrna."},{"key":"ref_71","unstructured":"Fierce Biotech (2026, May 01). BioNTech Fades Further Work on FixVac Vaccine Prospect in Advanced Melanoma Setting. Available online: https:\/\/www.fiercebiotech.com\/biotech\/biontech-fades-out-further-work-fixvac-vaccine-prospect-advanced-melanoma-setting."},{"key":"ref_72","unstructured":"Moderna, Inc. (2026, May 01). Moderna Research and Development Pipeline. Available online: https:\/\/www.modernatx.com\/research\/product-pipeline."},{"key":"ref_73","unstructured":"National Cancer Institute Drug Dictionary (2026, June 01). Cancer Antigen-Encoding mRNA Vaccine mRNA-4359 [Drug-Dictionary Source; Cited for Mechanism, Confirming IDO1 and PD-L1 targeting]. National Cancer Institute, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/mrna-4359."},{"key":"ref_74","unstructured":"Moderna, Inc. (2026, May 01). Moderna to Present Phase 1\/2 Data on Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma. Available online: https:\/\/www.biospace.com\/press-releases\/moderna-to-present-phase-1-2-data-on-its-investigational-cancer-antigen-therapy-mrna-4359-as-first-line-therapy-in-combination-with-pembrolizumab-in-locally-advanced-or-metastatic-melanoma-at-the-2026-aacr-annual-meeting."},{"key":"ref_75","unstructured":"Everest Medicines (2026, May 01). First Patient Dosed in a Global Multicenter Phase 1 Trial of Tumor-Associated-Antigen Cancer Vaccine EVM14. PR Newswire, Available online: https:\/\/www.prnewswire.com\/apac\/news-releases\/everest-medicines-announces-first-patient-dosed-in-a-global-multi-center-phase-i-clinical-trial-of-tumor-associated-antigen-cancer-vaccine-evm14-302622741.html."},{"key":"ref_76","unstructured":"CureVac N.V. (2026, May 01). CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for CVHNLC in Squamous non-Small-Cell Lung Cancer. Available online: https:\/\/www.curevac.com\/wp-content\/uploads\/2025\/04\/20250406-PR-CureVac-NSCLC-IND-Clearance-EN.pdf."},{"key":"ref_77","unstructured":"CureVac N.V. (2026, May 01). First Quarter 2025 Financial Results and Business Updates. Available online: https:\/\/www.curevac.com\/wp-content\/uploads\/2025\/05\/20250520-PR-CureVac-Q1-2025-Results_EN.pdf."},{"key":"ref_78","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: Gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"McCabe","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Arrieta-Bola\u00f1os, E., Hern\u00e1ndez-Zaragoza, D.I., and Barquera, R. (2023). An HLA map of the world: A comparison of HLA frequencies in 200 worldwide populations reveals diverse patterns for class I and class II. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.866407"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2338612","DOI":"10.1001\/jamanetworkopen.2023.38612","article-title":"Eligibility for human leukocyte antigen-based therapeutics by race and ethnicity","volume":"6","author":"Olivier","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"23667","DOI":"10.1038\/s41598-025-06704-4","article-title":"High resolution class I HLA-A, -B, and -C diversity in Eastern and Southern African populations","volume":"15","author":"Banjoko","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Shivarov, V., Tsvetkova, G., Micheva, I., Hadjiev, E., Petrova, J., Ivanova, A., Madjarova, G., and Ivanova, M. (2024). Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1427810"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1182\/blood.V98.10.2887","article-title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein","volume":"98","author":"Clark","year":"2001","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2141.2000.02090.x","article-title":"b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia","volume":"109","author":"Norbury","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.virol.2008.11.017","article-title":"Papillomavirus E6 proteins","volume":"384","author":"Howie","year":"2009","journal-title":"Virology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-0463.2010.02618.x","article-title":"Interaction of viral oncoproteins with cellular target molecules: Infection with high-risk versus low-risk human papillomaviruses","volume":"118","author":"Pim","year":"2010","journal-title":"APMIS"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/viro.2000.0794","article-title":"Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells","volume":"281","author":"Smahel","year":"2001","journal-title":"Virology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1084\/jem.20171046","article-title":"Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy","volume":"215","author":"Chheda","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.omto.2023.08.005","article-title":"Endogenous H3.3K27M derived peptide restricted to HLA-A*02:01 is insufficient for immune-targeting in diffuse midline glioma","volume":"30","author":"Wang","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"Reijmers","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/359162a0","article-title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","volume":"359","author":"Delattre","year":"1992","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.1998.16.4.1248","article-title":"EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing\u2019s sarcoma","volume":"16","author":"Kawai","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"16272","DOI":"10.1073\/pnas.0806526105","article-title":"T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus","volume":"105","author":"Shuda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/7\/1015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:23:58Z","timestamp":1784175838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/7\/1015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":96,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["biom16071015"],"URL":"https:\/\/doi.org\/10.3390\/biom16071015","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}